Abstract
N/A
Highlights
• Both Phase 3 studies met the co-primary endpoints of IGA success
in both studies • A reduction in mean inflammatory count was seen
ACKNOWLEDGEMENTS Study funded by Sol-Gel Technologies Ltd
Summary
• Rosacea affects at least 10% of fair skinned individuals and not uncommon in Black, Asian, and Hispanic populations1,7,8 • Over 16 million people in the United States have rosacea2 • Triggers for rosacea are wide-ranging and can include skin care products, cold and/or hot weather, spicy foods, and emotional stress1 • Rosacea is characterized as an inflammatory disorder of the facial skin that primarily affects the cheeks, nose, chin, forehead, and eyes1 • Rosacea signs present as facial erythema, flushing, papules, pustules, phymas, and telangiectasias1,7 • The disease is frequently characterized by remissions and exacerbations1 • Creates a silicon dioxide (silica) microcapsule shell between the BPO and the skin5 • Helps control the release rate of the drug to improve tolerability6 • Can preserve the advantages of BPO while minimizing limitations6 Silica is added in 5–100 repetitive cycles to build up a silica shell around the BPO IGA: Moderate IGA: Severe Mean lesion count (SD) Median lesion count (range) Mean age (years) Male Female
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
